Akari Therapeutics Announces Strategic Update in CEO Corner Segment

Corporate Update Highlights Significant Progress

Akari Therapeutics, Plc (NASDAQ: AKTX), an innovative oncology biotechnology company, has released a new segment of its CEO Corner featuring President and CEO Abizer Gaslightwala. This segment provides a comprehensive update on the company’s advancements in 2025 and outlines its strategic path toward becoming a clinical-stage oncology firm in 2026.

Innovative Developments in Antibody-Drug Conjugates

Utilizing its proprietary payload platform, Akari is pioneering a new class of immuno-oncology antibody-drug conjugates (ADCs). The key innovation is the PH1 payload, which is designed for a dual mechanism of action: directly inducing tumor cell death while simultaneously activating the immune system. This novel payload has shown a notable preclinical safety and efficacy profile, setting the stage for future clinical applications.

Key Milestones Achieved in 2025

In the past year, Akari made significant strides, including:

• Announcing a strategic manufacturing partnership with WuXi Biologics.
• Initiating Chemistry, Manufacturing, and Controls (CMC) and other pre-filing activities to enhance clinical readiness.
• Planning to commence its First-in-Human clinical trials by the end of 2026.

Pipeline Highlights and Future Aspirations

Akari's lead candidate, AKTX-101, specifically targets the Trop2 receptor on cancer cells, minimizing off-target effects while delivering the innovative PH1 payload directly into tumors. Unlike traditional ADCs that rely on inhibitors, PH1 modulates RNA splicing, showing significant preclinical efficacy in furthering cancer cell apoptosis.

Notably, AKTX-101 has displayed substantial activity and increased survival rates compared to standard ADCs. Furthermore, it has the potential to complement checkpoint inhibitors, showcasing enhanced therapeutic effects in preclinical studies.

Expanded Development Pipeline

Akari is also making progress on additional candidates, specifically:

• AKTX-101, with IND-enabling studies underway, aiming for a First-in-Human trial by late 2026 or early 2027.
• AKTX-102, an ADC targeting a novel antigen relevant in gastrointestinal and lung cancers.

Both candidates represent the company's commitment to advancing cutting-edge treatments in oncology.

Connect with Akari Therapeutics

For more insights and to view the full CEO Corner segment, visit www.akaritx.com and follow Akari Therapeutics on social media platforms like X and LinkedIn.

Forward-Looking Statements Disclaimer

This update contains forward-looking statements that entail risks and uncertainties regarding Akari's future performance and product developments. Actual results may differ materially from those indicated. Key factors include the need for additional capital, potential research delays, competition, and the successful commercialization of its product candidates. For more detailed information, please consult Akari's SEC filings.